Research Article

Investigating the Pretreatment miRNA Expression Patterns of Advanced Hepatocellular Carcinoma Patients in Association with Response to TACE Treatment

Table 2

Clinicopathological characteristics of 15 patients with advanced HCC treated with TACE.

Patient IDAgeHCV/cirrhosisPresentation AFP (ng/mL)GradeTNM stageChild-Pugh classOKUDA stageCLIPResponse score

Responders
P149.00+/+Jaundice16.002.00T1B231.00
P242.00NDPain3.002.00T1BND11.00
P352.00NDPain969.00NDT3bB241.00
P452.00+/−ND 1070003.00T1B242.00
P550.00−/+ND342.003.00T1BND12.00

Nonresponders
P643.00NDPain276.002.00T2ND214.00
P757.00−/+ND4.002.00T1B113.00
P859.00−/+PainND2.00T2A224.00
P957.00−/+ND28.00NDT2B223.00
P1052.00NDPain90.001.00T3aB234.00
P1161.00NDAscites350.002.00T2B225.00
P1258.00−/+ND2580.00NDT3aB245.00
P1367.00NDRecurrence978.002.00T3aA233.00
P1456.00+/+NDND2.00T1A103.00
P1558.00−/+Pain10.002.00T2B234.00

TNM: tumor, node, and metastases; AFP: alpha-fetoprotein; ND: not defined; CLIP: Cancer of the Liver Italian Program.